

10593748

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 OCT 04 Precision of EMBASE searching enhanced with new
chemical name field
NEWS 3 OCT 06 Increase your retrieval consistency with new formats or
for Taiwanese application numbers in CA/CAPLUS.
NEWS 4 OCT 21 CA/CAPLUS kind code changes for Chinese patents
increase consistency, save time
NEWS 5 OCT 22 New version of STN Viewer preserves custom
highlighting of terms when patent documents are
saved in .rtf format
NEWS 6 OCT 28 INPADOCDB/INPAFAMDB: Enhancements to the US national
patent classification.
NEWS 7 NOV 03 New format for Korean patent application numbers in
CA/CAPLUS increases consistency, saves time.
NEWS 8 NOV 04 Selected STN databases scheduled for removal on
December 31, 2010
NEWS 9 NOV 18 PROUSDDR and SYNTHLINE Scheduled for Removal
December 31, 2010 by Request of Prous Science
NEWS 10 NOV 22 Higher System Limits Increase the Power of STN
Substance-Based Searching
NEWS 11 NOV 24 Search an additional 46,850 records with MEDLINE
backfile extension to 1946
NEWS 12 DEC 14 New PNK Field Allows More Precise Crossover among STN
Patent Databases
NEWS 13 DEC 18 ReaxysFile available on STN
NEWS 14 DEC 21 CAS Learning Solutions -- a new online training experience
NEWS 15 DEC 22 Value-Added Indexing Improves Access to World Traditional
Medicine Patents in CAPLUS
NEWS 16 JAN 24 The new and enhanced DPCI file on STN has been released
NEWS 17 JAN 26 Improved Timeliness of CAS Indexing Adds Value to
USPATFULL and USPAT2 Chemistry Patents
NEWS 18 JAN 26 Updated MeSH vocabulary, new structured abstracts, and
other enhancements improve searching in STN reload of
MEDLINE
NEWS 19 JAN 28 CABA will be updated weekly

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

10593748

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:46:19 ON 22 FEB 2011

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.23	0.23

FILE 'REGISTRY' ENTERED AT 09:46:58 ON 22 FEB 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 FEB 2011 HIGHEST RN 1263357-65-8

DICTIONARY FILE UPDATES: 21 FEB 2011 HIGHEST RN 1263357-65-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

10593748

=>

Uploading C:\Program Files\Stnexp\Queries\10593748.str



chain nodes :
7 8 11 12 13 14 15 16 17 18
ring nodes :
1 2 3 4 5
chain bonds :
3-14 4-7 7-8 8-11 8-12 8-13 14-15 14-16 15-17 15-18
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 3-14 4-5 4-7 7-8 8-11 8-12 8-13 14-15 14-16 15-17
15-18
isolated ring systems :
containing 1 :

G1:O,S,N,CH2

G2:CH2,NH


G3:Cb,Cy,Hy,Ak,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 11:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

10593748

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O, S, N, CH2
G2 CH2, NH
G3 Cb, Cy, Hy, Ak, Ph

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:47:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 29 TO ITERATE

100.0% PROCESSED 29 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 257 TO 903
PROJECTED ANSWERS: 33 TO 447

L2 12 SEA SSS SAM L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY 0.51
TOTAL SESSION 0.74

FILE 'HCAPLUS' ENTERED AT 09:47:24 ON 22 FEB 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

10593748

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Feb 2011 VOL 154 ISS 9
FILE LAST UPDATED: 21 Feb 2011 (20110221/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.99	3.73

FILE 'REGISTRY' ENTERED AT 09:47:34 ON 22 FEB 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 FEB 2011 HIGHEST RN 1263357-65-8
DICTIONARY FILE UPDATES: 21 FEB 2011 HIGHEST RN 1263357-65-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s ll sss full

FULL SEARCH INITIATED 09:47:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 589 TO ITERATE

100.0% PROCESSED 589 ITERATIONS 229 ANSWERS
SEARCH TIME: 00.00.01

10593748

L3 229 SEA SSS FUL L1

=> FIL HCAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

196.86

200.59

FILE 'HCAPLUS' ENTERED AT 09:47:45 ON 22 FEB 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Feb 2011 VOL 154 ISS 9

FILE LAST UPDATED: 21 Feb 2011 (20110221/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

HCAPLUS now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 5 L3

=> s l4 and py<=2004

25160617 PY<=2004

L5 3 L4 AND PY<=2004

=> d l5 ibib abs hitstr tot


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2002:539654 HCAPLUS
 DOCUMENT NUMBER: 137:93692
 TITLE: Preparation of
 (quinolinylmethoxyphenylsulfonylmethyl)-substituted
 pyrrolidinecarboxamides and piperidinecarboxamides as
 MMP, TNF, and/or aggrecanase inhibitors
 INVENTOR(S): Xue, Chu-Biao; Decicco, Carl P.; He, Xiaohua
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company Patent Department, USA
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055491	A2	20020718	WO 2002-US760	20020109
WO 2002055491	A3	20030123		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2434044	A1	20020718	CA 2002-2434044	20020109
AU 2002246983	A1	20020724	AU 2002-246983	20020109
US 20030087890	A1	20030508	US 2002-43541	20020109
US 6642255	B2	20031104		
EP 1355648	A2	20031029	EP 2002-714733	20020109
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2001-260957P	P 20010111
			WO 2002-US760	W 20020109



ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 137:93692
 GI

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 exhibited K_i values of $\leq 10 \mu\text{M}$ against MMP-1, 2, 3, 9, and 13.
 Thus, I are useful for the treatment of inflammatory disorders and thromboembolic disorder (no data).
 IT 441297-34-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (MMP, TNF, and/or aggrecanase inhibitor; preparation of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors)
 RN 441297-34-3 HCAPLUS
 CN 1-Pyrrolidinecarboxylic acid,
 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, 1,1-dimethylethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 441297-33-2
 CMF C28 H33 N3 O7 S
 Absolute stereochemistry.



PAGE 1-A


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



AB Title compds. I [wherein A = COR5, CO2H, CH2CO2H, CO2R6, CONHOH, CONHOR5, CONHOR6, N(OH)CHO, N(OH)COR5, SH, CH2SH, SONHRa, SN2H2Ra, PO3H2, or PO(OH)NHRa; ring B = 3-10 membered (hetero)cyclyl; Z = absent or (un)substituted (hetero)cyclyl; U = absent or O, NH, N(alkyl), CO, CO2, OCO, CONH, NHCO, OCO2, etc. X = absent or alkylene, alkenylene, or alkynylene; Y = absent or O, NH, N(alkyl), SOO-2, or CO; Za = (un)substituted (hetero)cyclyl; R1a and R1b = independently H, alkyl, Ph, PhCH2, CH2OR3, or (un)substituted CH2NH2; or CR1aR1b = (hetero)cyclyl; R2 = Q or (un)substituted alkylene-Q, alkenylene-Q, or alkynylene-Q, Q-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.;
 R2a = H, alkyl, ORa, (un)substituted CH2NH2, or SOO-2Ra; R2b = H or alkyl; Q = H or (un)substituted (hetero)cyclyl; R3 = Q1 or (un)substituted alkylene-Q1, alkenylene-Q1, or alkynylene-Q1, Q1-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; or C(R3)2 = (un)substituted (hetero)cyclyl; Q1 = H or (un)substituted Ph, naphthyl, heteroaryl; Ra = H, alkyl, Ph, or PhCH2; p = 0-2; R5 = (un)substituted alkyl; R6 = phenyl(alkyl), naphthyl, cycloalkyl, alkylcarbonyloxy, etc.; or pharmaceutically acceptable salt thereof] were prepared as matrix metalloprotease (MMP), tumor necrosis factor (TNF), and aggrecanase inhibitors. For example, the 3-(quinolinylmethoxyphenylsulfonylmethyl)-4-piperidinecarboxamide (3R,4S)-II•2CF3CO2H was prepared in seventeen steps starting from the reaction of N-benzyloxycarbonyl-β-alanine and benzylbromide. Key steps include the cyclization of the 5-aminopentanal intermediate and the addition of 4-mercaptophenol and 4-chloromethyl-2-methylquinoline•HCl. A number of invention compds.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 441297-33-2P 441297-35-4P 441297-36-5P
 441297-37-6P 441297-38-7P 441297-39-8P
 441297-40-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (MMP, TNF, and/or aggrecanase inhibitor; preparation of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors)
 RN 441297-33-2 HCAPLUS
 CN 1-Pyrrolidinecarboxylic acid,
 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4S)- (CA INDEX NAME)
 Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 441297-35-4 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 441297-36-5 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 441297-35-4
 CMF C23 H25 N3 O5 S

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 441297-37-6 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 441297-38-7 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 441297-37-6
 CMF C26 H31 N3 O5 S

Absolute stereochemistry.

10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)


CRN 441297-39-8
CMF C26 H27 N3 O5 S

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

10593748.trn

02/22/2011

Page 9


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

RN 441297-39-8 HCAPLUS


CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propyn-1-yl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 441297-40-1 HCAPLUS

CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propyn-1-yl)-, (3R,4S)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

IT	1101037-97-1	1101037-98-2	1101037-99-3
	1101038-00-9	1101038-01-0	1101038-02-1
	1101038-03-2	1101038-04-3	1101038-05-4
	1101038-06-5	1101038-07-6	1101038-08-7
	1101038-09-8	1101038-10-1	1101038-11-2
	1101038-12-3	1101038-13-4	1101038-14-5
	1101038-15-6	1101038-16-7	1101038-17-8
	1101038-18-9	1101038-19-0	1101038-20-3
	1101038-21-4	1101038-22-5	1101038-23-6
	1101038-24-7	1101038-25-8	1101038-26-9
	1101038-27-0	1101038-28-1	1101038-29-2
	1101038-30-5	1101038-31-6	1101038-32-7
	1101038-33-8	1101038-34-9	1101038-35-0
	1101038-36-1	1101038-37-2	1101038-38-3
	1101038-39-4	1101038-40-7	1101038-41-8
	1101038-42-9	1101038-43-0	1101038-44-1
	1101038-45-2	1101038-46-3	1101038-47-4
	1101038-48-5	1101038-49-6	1101038-50-7
	1101038-51-8	1101038-52-9	1101038-53-0
	1101038-54-1	1101038-55-2	1101038-56-3
	1101038-57-4	1101038-58-5	1101038-59-6
	1101039-00-2	1101039-01-3	1101039-02-4
	1101039-03-5	1101039-04-6	1101039-05-7
	1101039-06-8	1101039-07-9	1101039-08-0
	1101039-09-1	1101039-10-4	1101039-11-5
	1101039-12-6	1101039-13-7	1101039-14-8
	1101039-15-9	1101039-16-0	1101039-17-1
	1101039-18-2	1101039-19-3	1101039-20-6
	1101039-21-7	1101039-22-8	1101041-14-8
	1101041-15-9	1101041-16-0	1101041-17-1
	1101041-18-2	1101041-19-3	1101041-20-6
	1101041-21-7	1101041-22-8	1101041-23-9
	1101041-24-0	1101041-25-1	1101041-26-2
	1101041-27-3	1101041-28-4	1101041-29-5
	1101041-30-8	1101041-31-9	1101041-32-0
	1101041-33-1	1101041-34-2	1101041-35-3
	1101041-36-4	1101041-37-5	1101041-38-6
	1101041-39-7	1101041-40-0	1101041-41-1
	1101041-84-2	1101041-85-3	1101041-86-4
	1101041-87-5	1101041-88-6	1101041-89-7
	1101041-90-0	1101041-91-1	1101041-92-2
	1101041-93-3	1101041-94-4	1101041-95-5
	1101041-96-6	1101041-97-7	1101041-98-8
	1101041-99-9	1101042-00-5	1101042-01-6
	1101042-02-7	1101042-03-8	1101042-04-9
	1101042-05-0	1101042-06-1	1101042-07-2
	1101042-08-3	1101042-09-4	1101042-10-7
	1101042-11-8	1101042-12-9	1101042-13-0
	1101042-14-1	1101042-15-2	1101042-16-3
	1101042-17-4	1101042-18-5	1101042-19-6
	1101042-20-9	1101042-21-0	1101042-22-1
	1101042-23-2	1101042-24-3	1101042-25-4
	1101042-26-5	1101042-27-6	1101042-28-7
	1101042-29-8	1101042-30-1	1101042-31-2
	1101042-32-3	1101042-33-4	1101042-34-5
	1101042-35-6	1101042-36-7	1101042-37-8
	1101042-38-9	1101042-39-0	1101042-40-3

10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

1101043-60-0 1101043-61-1 1101043-62-2
 1101043-63-3 1101043-64-4 1101043-65-5
 1101043-66-6 1101043-67-7 1101043-68-8
 1101043-69-9 1101043-70-2 1101043-71-3
 1101043-72-4 1101043-73-5 1101043-74-6
 1101043-75-7 1101043-76-8 1101043-77-9
 1101043-78-0 1101043-79-1 1101043-80-4
 1101043-81-5 1101043-82-6 1101043-83-7
 1101043-84-8 1101044-58-9 1101044-59-0
 1101044-60-3 1101044-61-4 1101044-62-5
 1101044-63-6 1101044-64-7 1101044-65-8


RL: PRPH (Prophetic)

(Preparation of (quinolinylmethoxyphenylsulfonylmethyl)-substituted
 pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or
 aggreganase inhibitors)

RN 1101037-97-1 HCAPLUS

CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(3-
 pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101037-98-2 HCAPLUS

CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(4-
 pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101037-99-3 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2,6-dimethyl-4-
 pyridinyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-00-9 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2-chloro-6-methyl-4-
 pyridinyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)-
 (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-01-0 HCAPLUS

CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2-chloro-6-methoxy-4-
 pyridinyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-02-1 HCAPLUS

CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(4-
 quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101038-03-2 HCAPLUS


CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(5-
 quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101038-04-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(6-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)


PAGE 1-A



RN 1101038-05-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-(5-isoquinolinylmethoxy)phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)


PAGE 2-A



RN 1101038-06-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-methyl-4-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 1101038-07-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-(2-methoxy-4-quinolinylmethoxy)phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 1101038-08-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(2-amino-4-quinolinylmethoxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 1101038-09-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-10-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101038-11-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-12-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-(2-(5-isoquinolinyl)ethoxy]phenyl)sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101038-13-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-(2-methyl-4-quinolinyl)ethoxy]phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-14-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-(2-(2-methoxy-4-quinolinyl)ethoxy]phenyl)sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-15-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(2-(2-amino-4-quinolinyl)ethoxy]phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-16-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[4-(phenoxymethyl)phenyl]sulfonyl]methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101038-17-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dimethylphenoxy)methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-18-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dichlorophenoxy)methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101038-19-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-bis(trifluoromethyl)phenoxy)methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-20-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2,6-dimethyl-4-pyridinyl)oxy)methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101038-21-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(4-pyridinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-22-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2-chloro-6-methyl-4-pyridinyl)oxy)methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-23-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

10593748


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-24-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(4-quinolinyl)oxy]methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 2-A



RN 1101038-26-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(6-quinolinyl)oxy]methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-27-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(5-isoquinolinyl)oxy]methyl]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)


PAGE 2-A



RN 1101038-25-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(5-quinolinyl)oxy]methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101038-28-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)oxy]methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101038-29-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[4-(1H-indol-5-yloxy)phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.




RN 1101038-33-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[4-[(1-methyl-1H-indol-5-yl)oxy]methyl]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-34-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[4-[(1-ethyl-1H-indol-5-yl)methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-35-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[4-(1H-indol-5-

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101038-30-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[4-[(1-methyl-1H-indol-5-yl)oxy]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-31-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[4-[(1-ethyl-1H-indol-5-yl)oxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101038-32-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[4-[(1H-indol-5-yl)oxy]methyl]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.




RN 1101038-36-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[4-[(1-methyl-1H-indol-5-yl)methoxy]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-37-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[4-(1H-benzimidazol-1-yl)methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-38-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[4-[(1-ethyl-1H-indol-5-

10593748


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 yl)methoxy]phenyl)sulfonylmethyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-39-4 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, 4-[[[4-[2-(1H-benzimidazol-1-yl)ethyl]phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101038-40-7 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, 4-[[[4-(1H-benzotriazol-1-yl)methyl]phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101038-41-8 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, 4-[[[4-[2-(1H-benzotriazol-1-yl)ethyl]phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-42-9 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2,4-dimethyl-5-thiazolyl)methoxy]phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 RN 1101038-43-0 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2,5-dimethyl-4-thiazolyl)methoxy]phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-44-1 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(4,5-dimethyl-2-thiazolyl)methoxy]phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-45-2 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[[2-(1-methylethyl)-4-thiazolyl)methoxy]phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101038-46-3 HCAPLUS


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(5-methyl-4-isoxazolyl)methoxy]phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-47-4 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[[2-(1-methylethyl)-5-thiazolyl)methoxy]phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-48-5 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, 4-[[[4-(2-butyn-1-yloxy)phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-49-6 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-pentyn-1-yloxy)phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

10593748


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.




RN 1101038-90-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[(4-ethoxyphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-91-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[(4-methylphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101038-92-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[4-methoxyphenyl)sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
methylthoxy)phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-96-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[4-(2-methylpropoxy)phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-97-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(1,1-dimethylethoxy)phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-98-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(cyclohexyloxy)phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


10593748.trn

02/22/2011

Page 17


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.




RN 1101038-93-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-ethoxyphenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-94-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[4-propoxyphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101038-95-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[4-(1-

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
Absolute stereochemistry.




RN 1101038-99-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(cyclobutyloxy)phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-00-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(cyclopentyloxy)phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101039-01-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(cyclohexyloxy)phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101039-02-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[(4-phenoxyphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




```

RN      1101039-03-5  HCAPLUS
CN      3-Pyrrolidinecarboxamide, 4-[[[4-(3,5-
(CA     dimethylphenoxy)phenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)-
        INDEX NAME)

```

Absolute stereochemistry.




RN 1101039-04-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(3,5-dichlorophenoxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)-
(CA

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)


3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(4-methylphenoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101039-08-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide,
4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]-
N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-09-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




```

RN      1101039-10-4  HCAPLUS
CN      3-Pyrrolidinecarboxamide, 4-[[[4-[(2,6-dimethyl-4-
pyridinyl)oxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA
INDEX NAME)

```


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry.




RN 1101039-05-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[4-(3-methylphenoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-06-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide,
4-[[[4-(3-chlorophenoxy)phenyl]sulfonyl]methyl]-
N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101039-07-9 HCAPLUS


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.




RN 1101039-11-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101039-12-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[4-(5-quinolinyl-2-yl)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)


RN 1101039-13-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(6-quinolinyl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-14-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-(5-isoquinolinyl)oxy]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101039-15-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-methyl-4-quinolinyl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101039-16-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(phenylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101039-17-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dimethylphenyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101039-18-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dichlorophenyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101039-19-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101039-20-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dibromophenyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101039-21-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-bis(trifluoromethyl)phenyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101039-22-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-trifluoromethylphenoxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101041-14-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-15-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1101041-16-0 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(2-chloro-5-pyridinyl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-17-1 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(5-quinolinyl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101041-18-2 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(6-quinolinyl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.



RN 1101041-19-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(5-isoquinolinyl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101041-20-6 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)oxy]methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-21-7 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(1H-indol-5-yloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101041-22-8 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(1-methyl-1H-indol-5-yloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101041-26-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101041-27-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(1-ethyl-1H-indol-5-yloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101041-28-4 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(1-methyl-1H-indol-5-yloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101041-23-9 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(1-ethyl-1H-indol-5-yloxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-24-0 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(1H-indol-5-yloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101041-25-1 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(1-methyl-1H-indol-5-yloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101041-29-5 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(1-ethyl-1H-indol-5-yloxy)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-30-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1101041-31-9 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[2-(1H-benzimidazol-1-yl)ethyl]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101041-32-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101041-33-1 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2,5-dimethyl-4-thiazolyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101041-34-2 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2,5-dimethyl-4-thiazolyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)


RN 1101041-37-5 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(2-(1-methylethyl)-5-thiazolyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101041-38-6 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(2-(1-methylethyl)-5-thiazolyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-39-7 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dimethyl-4-isoxazolyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101041-40-0 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2-butyn-1-yloxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.




RN 1101041-35-3 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2,5-dimethyl-2-thiazolyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101041-36-4 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2,4-dimethyl-5-thiazolyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.




RN 1101041-41-1 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(2-pentyn-1-yloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-84-2 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[(phenylsulfonyl)methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101041-85-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[(4-methylphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101041-86-4 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[4-methoxyphenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-87-5 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-ethoxyphenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101041-88-6 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-propoxyphenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101041-89-7 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(1-methylethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-90-0 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(2-methylpropoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101041-91-1 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(1,1-dimethylethoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101041-92-2 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(cyclobutyl)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-93-3 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(cyclobutyl)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101041-94-4 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(cyclopentyl)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101041-95-5 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(cyclohexyl)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-96-6 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(cyclohexyl)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101041-97-7 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(3,5-dimethylphenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101041-98-8 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(3,5-dichlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-99-9 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(3-methylphenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101042-00-5 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(3-chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101042-01-6 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-methylphenoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-02-7 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101042-03-8 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-pyridinyloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101042-04-9 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-(2,6-dimethyl-4-pyridinyloxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-05-0 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1101042-06-1 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(5-quinolin-2-yl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101042-07-2 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(6-quinolin-2-yl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-08-3 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(5-isoquinolin-2-yl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-09-4 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(2-methyl-4-quinolin-2-yl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748.trn

02/22/2011

Page 24


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101042-10-7 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(phenylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101042-11-8 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dimethylphenyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101042-15-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101042-16-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(2-pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101042-17-4 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(3-pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)


RN 1101042-12-9 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dichlorophenyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-13-0 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1101042-14-1 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dibromophenyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.




RN 1101042-18-5 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-19-6 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1101042-20-9 HCAPLUS

10593748.trn


02/22/2011

Page 25

10593748


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 CN 3-Furancarboxamide, 4-[[[4-[(2-chloro-6-methoxy-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)-
 (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-21-0 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-[(2-chloro-6-methoxy-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 1101042-22-1 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-23-2 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)


RN 1101042-24-3 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(6-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-25-4 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101042-26-5 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(2-methoxy-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-27-6 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1101042-28-7 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(4-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
Absolute stereochemistry.



RN 1101042-29-8 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(5-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101042-30-1 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(6-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-33-4 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(2-methoxy-4-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101042-34-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-31-2 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(5-isoquinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1101042-32-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(2-methyl-4-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 1101042-35-6 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dimethylphenoxy)methyl]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-36-7 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(phenoxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



10593748


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 RN 1101042-37-8 HCAPLUS
 CN 3-Furancarboxamide, 4-[[[4-[(3,5-dichlorophenoxy)methyl]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-38-9 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1101042-39-0 HCAPLUS
 CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(4-pyridinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-40-3 HCAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1101043-60-0 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-phenyl-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-61-1 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-pyridinyl)-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-62-2 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-63-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(4-pyridinyl)-, (3R,4S)-
(CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-64-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-acetyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-65-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(1-oxopropyl)-, (3R,4S)-
(CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-66-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(1-oxobutyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-67-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(2-methyl-1-oxopropyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-68-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(2,2-dimethyl-1-oxopropyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-69-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-pyridinylcarbonyl)-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-70-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinylcarbonyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-71-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(4-pyridinylcarbonyl)-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-72-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(methylsulfonyl)-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-73-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(phenylsulfonyl)-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-74-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-pyridinylsulfonyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-75-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinylsulfonyl)-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-76-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(4-pyridinylsulfonyl)-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-77-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-78-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, propyl ester, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-79-1 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid,
3-[(hydroxyamino)carbonyl]-4-[[4-[(2-methyl-
4-quinolinyl)methoxy]phenyl]sulfonylmethyl]-, 1-methylethyl ester,
(3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-80-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-81-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-82-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-83-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101043-84-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101044-58-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-ethyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101044-59-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-propyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

10593748

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101044-60-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-butyl-N-hydroxy-4-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101044-61-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(2-methylpropyl)-4-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101044-62-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-cyclobutyl-N-hydroxy-4-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101044-63-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-cyclohexyl-N-hydroxy-4-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101044-64-7 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, 1-cyclopentyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 1101044-65-8 HCAPLUS
 CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propen-1-yl)-, (3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS
 RECORD (1 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN


ACCESSION NUMBER: 2001:876610 HCAPLUS
 DOCUMENT NUMBER: 136:19953
 TITLE: Preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF-α converting enzyme inhibitors.
 INVENTOR(S): Levin, Jeremy I.; Chen, James M.; Zask, Arie
 PATENT ASSIGNEE(S): American Cyanamid Company, USA
 SOURCE: U.S., 21 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6326516	B1	20011204	US 2000-492980	20000127

<--
 PRIORITY APPLN. INFO.: US 1999-155250P P 19990127

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 136:19953
 AB RSC.tplbond.CCR6R7ZYXNR5CHR11CHR12CONHOH,
 RSC.tplbond.CCR6R7ZYXNR5CHR11:CR12CONHOH [X = SO₂, P(O)R₁₀; Y =
 heteroaryl,
 Ph, naphthyl; Z = O, NH, CH₂, S; R₅ = H, alkyl; R₆, R₇ = H, Me; R₈ = H,
 alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, Ph, etc.; R₁₀ = alkyl,
 cycloalkyl, Ph, heteroaryl; R₁₁, R₁₂ = H, alkyl, cycloalkyl, heteroaryl,
 Ph; R₁₁R₁₂ = atoms to form (fused) (unsatd.) ring; with provisos], were
 prepared Thus,
 (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl](methyl)amino]-
 N-hydroxycyclopentanecarboxamide (general preparation given) inhibited
 TNF-α converting enzyme (ACE) with IC₅₀ = 14 nM.
 IT 376630-57-8P, (1R,2S)-2-[[[4-(2-
 Butynyloxy)phenyl]sulfonyl]amino]-N-hydroxycyclopentanecarboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF-α
 converting enzyme inhibitors)
 RN 376630-57-8 HCAPLUS
 CN Cyclopentanecarboxamide,
 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-
 hydroxy-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS
 RECORD


10593748

L5 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
(7 CITINGS)
REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L5 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2000:535104 HCAPLUS
DOCUMENT NUMBER: 133:150361
TITLE: Preparation of
alkynyloxyphenylsulfonylaminoalkylhydroxamic acids
and
related compounds as TNF- α converting enzyme
(TACE) inhibitors.
INVENTOR(S): Levin, Jeremy Ian; Chen, James Ming; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044711	A1	20000803	WO 2000-US1865	20000127
<--				
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MM, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356345	A1	20000803	CA 2000-2356345	20000127
<--				
EP 1147078	A1	20011024	EP 2000-904570	20000127
<--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007754	A	20011113	BR 2000-7754	20000127
<--				
HU 2002000605	A2	20020729	HU 2002-605	20000127
<--				
HU 2002000605	A3	20050530		
JP 2002535383	T	20021022	JP 2000-595968	20000127
<--				
NZ 512025	A	20030829	NZ 2000-512025	20000127
<--				
AU 769410	B2	20040129	AU 2000-26306	20000127
<--				
ZA 2001004508	A	20020902	ZA 2001-4508	20010531
<--				
NO 2001003639	A	20010724	NO 2001-3639	20010724
<--				
MX 2001007465	A	20011203	MX 2001-7465	20010724
<--				
PRIORITY APPLN. INFO.:			US 1999-239083	A 19990127
			WO 2000-US1865	W 20000127

L5 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 133:150361
GI



AB Title compds. (I; X = SO₂, FOR10; Y = 5-10 membered heteroaryl, Ph, naphthyl; Z = O, NH, CH₂, S; R₅ = H, alkyl; R₆, R₇ = H, Me; R₈ = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycloalkyl, Ph; R₉ = H, alkyl, cycloalkyl, Ph; R₁₀ = alkyl, cycloalkyl, Ph, heteroaryl; R₁₁, R₁₂ = H, alkyl, cycloalkyl, heteroaryl, heterocycloalkyl; R₁₁R₁₂ = atoms to form 5-10 membered mono- or bicyclic (heterocyclic) ring, Ph, naphthyl; dotted line = optional double bond), were prepared. Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxycyclopentanecarboxamide [preparation from cis-2-amino-1-cyclopentanecarboxylic acid and 4-(2-butynyloxy)phenylsulfonyl chloride given] inhibited TACE with IC₅₀ = 14 nM.
IT 287096-61-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of alkynyloxyphenylsulfonylaminoalkylhydroxamic acids and related compds. as TNF- α converting enzyme inhibitors)
RN 287096-61-1 HCAPLUS
CN Cyclopentanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)-rel- (CA INDEX NAME)
Relative stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

10593748.trn

02/22/2011


Page 37

10593748

=> d l4 ibib abs tot

10593748

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2008:1088521 HCAPLUS
 DOCUMENT NUMBER: 149:513677
 TITLE: Development of a Suitable Process for the Preparation of a TNF- α Converting Enzyme Inhibitor, WAY-281418
 AUTHOR(S): Wang, Youchu; Papamichelakis, Maria; Chew, Warren; Sellstedt, John; Noureldin, Razzak; Tadayon, Sam; Daigneault, Sylvain
 CORPORATE SOURCE: Chemical Development, Wyeth Research, Saint-Laurent, QC, H4R 1J6, Can.
 SOURCE: Organic Process Research & Development (2008), 12(6), 1253-1260
 CODEN: OPRDFK; ISSN: 1083-6160
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 149:513677
 GI




AB A suitable process for the preparation of kilogram quantities of a TNF- α converting enzyme (TACE) inhibitor (WAY-281418) was developed using isatin as starting material and an efficient coupling step for the formation of sulfonamide I in a 15% overall yield. Process preparation of (+)-(1S,2R)-2-aminocyclopentane-1-carboxylic acid (II, (+)-cis-pentacin), a chiral component for WAY-281418, was successfully scaled up via an asym. hydrogenation reaction. Crystallization allowed the isolation of all intermediates and the final product III.

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2006:979177 HCAPLUS
 DOCUMENT NUMBER: 145:356664
 TITLE: Preparation of β -sulfonamide hydroxamic acid inhibitors of TACE/matrix metalloproteinase
 INVENTOR(S): Levin, Jeremy I.; Li, Zhong; Diamantidis, George; Lovering, Frank E.; Wang, Weiheng; Condon, Jeffrey S.;
 Lin, Yang-I.; Skotnicki, Jerrold S.; Park, Kaapjoo
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 61pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060211730	A1	20060921	US 2006-377886	20060316
US 7595327	B2	20090929		

PRIORITY APPLN. INFO.: US 2005-663785P P 20050321

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 145:356664; MARPAT 145:356664
 GI



AB This invention provides compds. of formula I (wherein J = (un)substituted a monocyclic or bicyclic 5-8 membered cycloalkyl or heterocycloalkyl; R2 = H, (un)substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; R3 = (un)substituted naphthyl or bicyclic heteroaryl; R4 and R5 = independently H, (un)substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; R8 and R9 = independently H, OH, substituted amino, halo, C1-C6 alkyl, etc.; E = -C(=C)-, -C(=N)-, -N(=C)-, S or O; X = O, S(O)n, or substituted amino; n = 0-2) that are useful in treating diseases or disorders mediated by TNF- α , such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc.), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compds. Preparation of I is exemplified. For example,

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 prepd. by reacting 3-endo-aminobicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid with 4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl chloride hydrochloride and reacting the intermediate formed with hydroxylamine.
 In an assay involving cleavage of pro-TNF by TACE, II had an IC50 of 1.2 nM.
 OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)



10593748

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2002:539654 HCAPLUS
 DOCUMENT NUMBER: 137:93692
 TITLE: Preparation of
 (quinolinylmethoxyphenylsulfonylmethyl)-substituted
 pyrrolidinecarboxamides and piperidinecarboxamides as
 MMP, TNF, and/or aggrecanase inhibitors
 INVENTOR(S): Xue, Chu-Biao; Decicco, Carl P.; He, Xiaohua
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company Patent Department, USA
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055491	A2	20020718	WO 2002-US760	20020109
WO 2002055491	A3	20030123		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
CA 2434044	A1	20020718	CA 2002-2434044	20020109
AU 2002246983	A1	20020724	AU 2002-246983	20020109
US 20030087890	A1	20030508	US 2002-43541	20020109
US 6642255	B2	20031104		
EP 1355648	A2	20031029	EP 2002-714733	20020109
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2001-260957P	P 20010111
			WO 2002-US760	W 20020109

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 137:93692
 GI

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



AB Title compds. I [wherein A = COR5, CO2H, CH2CO2H, CO2R6, CONHOH, CONHOR5, CONHOR6, N(OH)CHO, N(OH)COR5, SH, CH2SH, SONHRa, SN2H2Ra, PO3H2, or PO(OH)NHRa; ring B = 3-10 membered (hetero)cyclyl; Z = absent or (un)substituted (hetero)cyclyl; U = absent or O, NH, N(alkyl), CO, CO2, COO, CONH, NHCO, COO2, etc. X = absent or alkylene, alkenylene, or alkynylene; Y = absent or O, NH, N(alkyl), SOO-2, or CO; Z = (un)substituted (hetero)cyclyl; R1a and R1b = independently H, alkyl, Ph, PhCH2, CH2OR3, or (un)substituted CH2NH2; or CR1aR1b = (hetero)cyclyl; R2 = Q or (un)substituted alkylene-Q, alkenylene-Q, or alkynylene-Q, Q-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.;

R2a = H, alkyl, ORa, (un)substituted CH2NH2, or SOO-2Ra; R2b = H or alkyl; Q =

H or (un)substituted (hetero)cyclyl; R3 = Q1 or (un)substituted alkylene-Q1, alkenylene-Q1, or alkynylene-Q1, Q1-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; or C(R3)2 = (un)substituted (hetero)cyclyl; Q1 = H or (un)substituted Ph, naphthyl,

or heteroaryl; Ra = H, alkyl, Ph, or PhCH2; p = 0-2; R5 = (un)substituted alkyl; R6 = phenyl(alkyl), naphthyl, cycloalkyl, alkylcarbonyloxy, etc.; or pharmaceutically acceptable salt thereof] were prepared as matrix metalloprotease (MMP), tumor necrosis factor (TNF), and aggrecanase inhibitors. For example, the

3-(quinolinylmethoxyphenylsulfonylmethyl)-4-piperidinecarboxamide (3R,4S)-II•2CF3CO2H was prepared in seventeen steps starting from the reaction of N-benzyloxycarbonyl-β-alanine and benzylbromide. Key steps include the cyclization of the 5-aminopentanal intermediate and the addition of 4-mercaptophenol and 4-chloromethyl-2-methylquinoline•HCl. A number of invention compds.

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 exhibited Ki values of ≤ 10 μM against MMP-1, 2, 3, 9, and 13.
 Thus, I are useful for the treatment of inflammatory disorders and thromboembolic disorder (no data).
 OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 REFERENCE COUNT: 1 (1 CITINGS)
 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2001:876610 HCAPLUS
 DOCUMENT NUMBER: 136:19953
 TITLE: Preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF-α converting enzyme inhibitors.
 INVENTOR(S): Levin, Jeremy I.; Chen, James M.; Zask, Arie
 PATENT ASSIGNEE(S): American Cyanamid Company, USA
 SOURCE: U.S., 21 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6326516	B1	20011204	US 2000-492980	20000127
PRIORITY APPLN. INFO.:			US 1999-155250P	P 19990127

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 136:19953

AB R8C.tplbond.CCR6R7ZYXNR5CHR11CHR12CONHOH,
 R8C.tplbond.CCR6R7ZYXNR5CHR11:CR12CONHOH [X = SO2, P(O)R10; Y = heteroaryl,
 Ph, naphthyl; Z = O, NH, CH2, S; R5 = H, alkyl; R6, R7 = H, Me; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, Ph, etc.; R10 = alkyl, cycloalkyl, Ph, heteroaryl; R11, R12 = H, alkyl, cycloalkyl, heteroaryl, Ph; R11R12 = atoms to form (fused) (unsatd.) ring; with provisos], were prepared. Thus,
 (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl](methyl)amino]-N-hydroxycyclopentanecarboxamide (general preparation given) inhibited TNF-α converting enzyme (TACE) with IC50 = 14 nM.

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD

(7 CITINGS)
 REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


10593748

L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2000:535104 HCAPLUS
DOCUMENT NUMBER: 133:150361
TITLE: Preparation of
alkynyloxyphenylsulfonaminoalkylhydroxamic acids
and
related compounds as TNF- α converting enzyme
(TACE) inhibitors.
INVENTOR(S): Levin, Jeremy Ian; Chen, James Ming; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044711	A1	20000803	WO 2000-US1865	20000127
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2356345	A1	20000803	CA 2000-2356345	20000127
EP 1147078	A1	20011024	EP 2000-904570	20000127
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000007754	A	20011113	BR 2000-7754	20000127
HU 2002000605	A2	20020729	HU 2002-605	20000127
HU 2002000605	A3	20050530		
JP 2002535383	T	20021022	JP 2000-595968	20000127
NZ 512025	A	20030829	NZ 2000-512025	20000127
AU 769410	B2	20040129	AU 2000-26306	20000127
ZA 2001004508	A	20020902	ZA 2001-4508	20010531
NO 2001003639	A	20010724	NO 2001-3639	20010724
MX 2001007465	A	20011203	MX 2001-7465	20010724
PRIORITY APPLN. INFO.:			US 1999-239083	A 19990127
			WO 2000-US1865	W 20000127

OTHER SOURCE(S): MARPAT 133:150361
GI

L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



AB Title compds. (I; X = SO₂, FOR10; Y = 5-10 membered heteroaryl, Ph, naphthyl; Z = O, NH, CH₂, S; R₅ = H, alkyl; R₆, R₇ = H, Me; R₈ = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycloalkyl, Ph; R₉ = H, alkyl, cycloalkyl, Ph; R₁₀ = alkyl, cycloalkyl, Ph, heteroaryl; R₁₁, R₁₂ = H, alkyl, cycloalkyl, heteroaryl, heterocycloalkyl; R₁₁R₁₂ = atoms to form 5-10 membered mono- or bicyclic (heterocyclic) ring, Ph, naphthyl; dotted line = optional double bond), were prepared Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxycyclopentanecarboxamide [preparation from cis-2-amino-1-cyclopentanecarboxylic acid and 4-(2-butynyloxy)phenylsulfonyl chloride given] inhibited TACE with IC₅₀ = 14 nM.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

10593748

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

69.76

270.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-6.96

-6.96

FILE 'REGISTRY' ENTERED AT 09:55:08 ON 22 FEB 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 FEB 2011 HIGHEST RN 1263357-65-8

DICTIONARY FILE UPDATES: 21 FEB 2011 HIGHEST RN 1263357-65-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10593748a.str

10593748



chain nodes :
7 8 11 12 13 14 15 16 17 18
ring nodes :
1 2 3 4 5
chain bonds :
3-14 4-7 7-8 8-11 8-12 8-13 14-15 14-16 15-17 15-18
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
4-7 7-8 8-11 8-12 8-13 14-15 14-16 15-18
exact bonds :
1-2 1-5 2-3 3-4 3-14 4-5 15-17
isolated ring systems :
containing 1 :

G1:O,S,N,CH2

G2:CH2,NH

G3:Cb,Cy,Hy,Ak,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 11:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS


10593748

L6 STRUCTURE UPLOADED

=> d 16

L6 HAS NO ANSWERS

L6 STR



G1 O, S, N, CH₂

G2 CH₂, NH

G3 Cb, Cy, Hy, Ak, Ph

Structure attributes must be viewed using STN Express query preparation.

=> s 16

SAMPLE SEARCH INITIATED 09:55:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 56 TO 504

PROJECTED ANSWERS: 6 TO 266

L7 6 SEA SSS SAM L6

=> s 16 sss full

FULL SEARCH INITIATED 09:55:48 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 154 TO ITERATE

100.0% PROCESSED 154 ITERATIONS

36 ANSWERS

SEARCH TIME: 00.00.01

L8 36 SEA SSS FUL L6

=> FIL HCAPLUS

10593748

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	196.86	467.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-6.96

FILE 'HCAPLUS' ENTERED AT 09:55:52 ON 22 FEB 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Feb 2011 VOL 154 ISS 9
FILE LAST UPDATED: 21 Feb 2011 (20110221/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

HCAPLUS now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l8

L9 7 L8

=> s l9 and py<=2004

25160617 PY<=2004

L10 3 L9 AND PY<=2004

=> d l10 ibib abs hitstr tot

10593748

L10 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2001:876610 HCAPLUS
 DOCUMENT NUMBER: 136:19953
 TITLE: Preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF- α converting enzyme inhibitors.
 INVENTOR(S): Levin, Jeremy I.; Chen, James M.; Zask, Arie
 PATENT ASSIGNEE(S): American Cyanamid Company, USA
 SOURCE: U.S., 21 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6326516	B1	20011204	US 2000-492980	20000127


<-- PRIORITY APPLN. INFO.: US 1999-155250P P 19990127

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 136:19953
 AB R8C.tplbond.CCR6R7ZYXNR5CHR11CHR12CONHOH,
 R8C.tplbond.CCR6R7ZYXNR5CHR11:CR12CONHOH [X = SO₂, P(O)R₁₀; Y = heteroaryl,
 Ph, naphthyl; Z = O, NH, CH₂, S; R₅ = H, alkyl; R₆, R₇ = H, Me; R₈ = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, Ph, etc.; R₁₀ = alkyl, cycloalkyl, Ph, heteroaryl; R₁₁, R₁₂ = H, alkyl, cycloalkyl, heteroaryl, Ph; R₁₁R₁₂ = atoms to form (fused) (unsatd.) ring; with provisos], were prepared Thus,
 (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl]amino]-N-hydroxycyclopentanecarboxamide (general preparation given) inhibited TNF- α converting enzyme (TACE) with IC₅₀ = 14 nM.
 IT 287096-63-3P, (cis)-2-[[[4-(2-Butynyloxy)phenyl]sulfonyl]amino]-N-hydroxycyclohexanecarboxamide 376630-56-7P,
 (1R,2R)-2-[[[4-(2-Butynyloxy)phenyl]sulfonyl]amino]-N-hydroxycyclohexanecarboxamide 376630-57-8P,
 (1R,2S)-2-[[[4-(2-Butynyloxy)phenyl]sulfonyl]amino]-N-hydroxycyclopentanecarboxamide 376630-59-0P,
 (1R,2R,3S,4R)-3-[[[4-(2-Butynyloxy)phenyl]sulfonyl]amino]-N-hydroxybicyclo[2.2.1]heptan-2-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF- α converting enzyme inhibitors)

RN 287096-63-3 HCAPLUS
 CN Cyclohexanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)-rel- (CA INDEX NAME)


Relative stereochemistry.

L10 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




RN 376630-56-7 HCAPLUS
 CN Cyclohexanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 376630-57-8 HCAPLUS
 CN Cyclopentanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 376630-59-0 HCAPLUS
 CN Bicyclo[2.2.1]heptane-2-carboxamide, 3-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)




OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
 (7 CITINGS)
 REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L10 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2000:553546 HCAPLUS
 DOCUMENT NUMBER: 133:150358
 TITLE: Preparation of sulfonamide derivatives having cyclic structures as matrix metalloprotease inhibitors and TNF production inhibitors
 INVENTOR(S): Watanabe, Fumihiko; Tsuzuki, Hiroshige
 PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046189	A1	20000810	WO 2000-JP446	20000128

<-- W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: JP 1999-25058 A 19990202

OTHER SOURCE(S): MARPAT 133:150358
 GI




AB The title derivs. I [A is Q1, etc.; R1 is COOR6 or the like; R6 is hydrogen, alkyl; R2 is optionally substituted arylene or the like; R3 is CONH or the like; R4 is optionally substituted aryl or the like; R5 is hydrogen or the like; and m and n are each independently 0 or 1] are prepared. The title compound II in vitro showed IC₅₀ of 9.7 μ M against MMP-8. Formulations are given.
 IT 287395-23-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological)

10593748

L10 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of sulfonamide derivs. having cyclic structures as matrix
 metalloprotease inhibitors and TNF prodn. inhibitors)
 RN 287395-23-7 HCAPLUS
 CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide,
 3-[[[5-[4-(dimethylamino)phenyl]-2-thienyl]sulfonyl]amino]-N-hydroxy-,
 (1S,2S,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS
 RECORD
 (6 CITINGS)
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L10 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2000:535104 HCAPLUS
 DOCUMENT NUMBER: 133:150361
 TITLE: Preparation of
 alkynylloxyphenylsulfonylaminoalkylhydroxamic acids
 and
 related compounds as TNF- α converting enzyme
 (TACE) inhibitors.
 INVENTOR(S): Levin, Jeremy Ian; Chen, James Ming; Zask, Arie
 PATENT ASSIGNEE(S): American Cyanamid Company, USA
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044711	A1	20000803	WO 2000-US1865	20000127
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MM, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356345	A1	20000803	CA 2000-2356345	20000127
EP 1147078	A1	20011024	EP 2000-904570	20000127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO BR 2000007754 A 20011113 BR 2000-7754 20000127				
HU 2002000605	A2	20020729	HU 2002-605	20000127
HU 2002000605	A3	20050530		
JP 2002535383	T	20021022	JP 2000-595968	20000127
NZ 512025	A	20030829	NZ 2000-512025	20000127
AU 769410	B2	20040129	AU 2000-26306	20000127
ZA 2001004508	A	20020902	ZA 2001-4508	20010531
NO 2001003639	A	20010724	NO 2001-3639	20010724
MX 2001007465	A	20011203	MX 2001-7465	20010724
PRIORITY APPLN. INFO.:				
			US 1999-239083	A 19990127
			WO 2000-US1865	W 20000127

L10 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 OTHER SOURCE(S): MARPAT 133:150361
 GI




AB Title compds. (I; X = SO₂, POR10; Y = 5-10 membered heteroaryl, Ph, naphthyl; Z = O, NH, CH₂, S; R₅ = H, alkyl; R₆, R₇ = H, Me; R₈ = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycloalkyl, Ph; R₉ = H, alkyl, cycloalkyl, Ph; R₁₀ = alkyl, cycloalkyl, Ph, heteroaryl; R₁₁, R₁₂ = H, alkyl, cycloalkyl, heteroaryl, heterocycloalkyl; R₁₁R₁₂ = atoms to form 5-10 membered mono- or bicyclic (heterocyclic) ring, Ph, naphthyl; dotted line = optional double bond), were prepared. Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxycyclopentanecarboxamide [preparation from cis-2-amino-1-cyclopentanecarboxylic acid and 4-(2-butynyloxy)phenylsulfonyl chloride given] inhibited TACE with IC₅₀ = 14 nM.
 IT 287096-58-6P 287096-61-1P 287096-63-3P
 287096-65-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of alkynylloxyphenylsulfonylaminoalkylhydroxamic acids and related compds. as TNF- α converting enzyme inhibitors)
 RN 287096-58-6 HCAPLUS
 CN Cyclohexanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 287096-61-1 HCAPLUS
 CN Cyclopentanecarboxamide,
 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)-rel- (CA INDEX NAME)

L10 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 Relative stereochemistry.




RN 287096-63-3 HCAPLUS
 CN Cyclohexanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 287096-65-5 HCAPLUS
 CN Bicyclo[2.2.1]heptane-2-carboxamide,
 3-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-,
 (1R,2S,3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS
 RECORD
 (4 CITINGS)
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

10593748.trn

02/22/2011

Page 47

10593748

L10 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)


10593748

=> d 19 ibib abs tot

10593748

L9 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2008:1088521 HCAPLUS
 DOCUMENT NUMBER: 149:513677
 TITLE: Development of a Suitable Process for the Preparation of a TNF- α Converting Enzyme Inhibitor, WAY-281418
 AUTHOR(S): Wang, Youchu; Papamichelakis, Maria; Chew, Warren; Sellstedt, John; Noureldin, Razzak; Tadayon, Sam; Daigneault, Sylvain
 CORPORATE SOURCE: Chemical Development, Wyeth Research, Saint-Laurent, QC, H4R 1J6, Can.
 SOURCE: Organic Process Research & Development (2008), 12(6), 1253-1260
 CODEN: OPRDFK; ISSN: 1083-6160
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 149:513677
 GI

L9 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 hydrogenation reaction. Crystn. allowed the isolation of all intermediates and the final product III.
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE




AB A suitable process for the preparation of kilogram quantities of a TNF- α converting enzyme (TACE) inhibitor (WAY-281418) was developed using isatin as starting material and an efficient coupling step for the formation of sulfonamide I in a 15% overall yield. Process preparation of (+)-(1S,2R)-2-aminocyclopentane-1-carboxylic acid (II, (+)-cis-pentacin), a chiral component for WAY-281418, was successfully scaled up via an asym.

L9 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2006:979177 HCAPLUS
 DOCUMENT NUMBER: 145:356664
 TITLE: Preparation of β -sulfonamide hydroxamic acid inhibitors of TACE/matrix metalloproteinase
 INVENTOR(S): Levin, Jeremy I.; Li, Zhong; Diamantidis, George; Lovering, Frank E.; Wang, Weiheng; Condon, Jeffrey S.;
 Lin, Yang-I.; Skotnicki, Jerauld S.; Park, Kaapjoo
 PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
 SOURCE: U.S. Pat. Appl. Publ., 61pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060211730	A1	20060921	US 2006-377886	20060316
US 7595327	B2	20090929		

PRIORITY APPLN. INFO.: US 2005-663785P P 20050321

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 145:356664; MARPAT 145:356664
 GI



AB This invention provides compds. of formula I (wherein J = (un)substituted a monocyclic or bicyclic 5-8 membered cycloalkyl or heterocycloalkyl; R2 =
 = H, (un)substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; R3 = (un)substituted naphthyl or bicyclic heteroaryl; R4 and R5 = independently
 H, (un)substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; R8 and R9 = independently H, OH, substituted amino, halo, C1-C6 alkyl, etc.; E = -C(=C-, -C=N-, -N=C-, S or O; X = O, S(O)n, or substituted amino; n = 0-2) that are useful in treating diseases or disorders mediated by TNF- α , such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc.), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for

L9 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 alleviation of symptoms thereof. The invention further provides methods for use of the compds. Prepn. of I is exemplified. For example, II was prepd. by reacting 3-endo-aminobicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid with 4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl chloride hydrochloride and reacting the intermediate formed with hydroxylamine.
 In an assay involving cleavage of pro-TNF by TACE, II had an IC50 of 1.2 nM.
 OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)



L9 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:757211 HCAPLUS
DOCUMENT NUMBER: 145:241166
TITLE: Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
AUTHOR(S): Zhou, Bin-Bing S.; Peyton, Michael; He, Biao; Liu, Changnian; Girard, Luc; Caudler, Eian; Lo, Yvonne; Baribaud, Frederic; Mikami, Iwao; Reguart, Noemi; Yang, Gengjie; Li, Yanlong; Yao, Wenqing; Vaddi, Garzar, Adi F.; Friedman, Steven M.; Jablons, David M.; Newton, Robert C.; Fridman, Jordan S.; Minna, D.; Scherle, Peggy A.
Kris; John
CORPORATE SOURCE: Drug Discovery, Experimental Station, Incyte Corporation, Wilmington, DE, 19880, USA
SOURCE: Cancer Cell (2006), 10(1), 39-50
CODEN: CCAECI; ISSN: 1535-6108
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC). ADAM17 protein, a major ErbB ligand sheddase, is upregulated in NSCLC and is required not only for heregulin-dependent HER3 signaling, but also for EGFR ligand-dependent signaling in NSCLC cell lines. A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple ErbB ligands, including heregulin. In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances gefitinib inhibition of EGFR signaling in NSCLC. These results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacol. intervention, either alone or in combination with other drugs.
OS.CITING REF COUNT: 98 THERE ARE 98 CAPLUS RECORDS THAT CITE THIS RECORD (99 CITINGS)
REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD.
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L9 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2005:1075765 HCAPLUS
DOCUMENT NUMBER: 143:346847
TITLE: Preparation of cyclohexylcarboxamide derivatives as inhibitors of matrix metalloproteinases
INVENTOR(S): Ananthan, Subramaniam
PATENT ASSIGNEE(S): Southern Research Institute, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXKD
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 1 English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092844	A1	20051006	WO 2005-US9263	20050321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GU, GW, ML, MR, NE, SN, TD, TG			
AU 2005227311	A1	20051006	AU 2005-227311	20050321
CA 2560739	A1	20051006	CA 2005-2560739	20050321
EP 1735274	A1	20061227	EP 2005-729212	20050321
EP 1735274	B1	20091125		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 101001834	A	20070718	CN 2005-80016346	20050321
JP 2007530546	T	20071101	JP 2007-505043	20050321
NZ 550621	A	20091127	NZ 2005-550621	20050321
PT 1735274	E	20091211	PT 2005-729212	20050321
AT 449760	T	20091215	AT 2005-729212	20050321
ES 2338243	T3	20100505	ES 2005-729212	20050321
MX 2006010974	A	20070423	MX 2006-10974	20060922
IN 2006DN05647	A	20070831	IN 2006-DN5647	20060928
KR 2007046025	A	20070502	KR 2006-7021920	20061023
US 20080312329	A1	20081218	US 2008-593748	20080728
PRIORITY APPLN. INFO.:			US 2004-555380P	P 20040322
			WO 2005-US9263	W 20050321

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:346847; MARPAT 143:346847
GI

L9 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



AB Title compds. I [X = (CH₂)_nO, (CH₂)_nS, (CH₂)_n(CH₂), etc.; n = 0-2; R = (un)substituted alkyl, alkenyl, alkynyl, etc.; Z = NH or CH₂] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of matrix metalloproteinases (MMP). Thus, e.g., II was prepared by sulfonylation of cis-2-amino-1-cyclohexanecarboxylic acid with biphenyl-4-sulfonyl chloride and subsequent amidation using O-(trimethylsilyl)hydroxylamine. The inhibitory activity of I towards MMP-2, MMP-3 and MMP-9 was evaluated using fluorometric substrate-degradation assays and it was revealed that selected compds. of the invention displayed IC₅₀ values in the range of 125 up to 150 nM against MMP-2, 145 up to 175 nM against MMP-9 and above 3000 nM against MMP-3. I as inhibitors of matrix metalloproteinases should prove useful in the treatment of leukemia, melanoma and carcinoma. Pharmaceutical compns. comprising I are disclosed.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD.
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L9 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2001:876610 HCAPLUS
DOCUMENT NUMBER: 136:19953
TITLE: Preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF-α converting enzyme inhibitors.
INVENTOR(S): Levin, Jeremy I.; Chen, James M.; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: U.S., 21 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6326516	B1	20011204	US 2000-492980	20000127
PRIORITY APPLN. INFO.:			US 1999-155250P	P 19990127


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:19953
AB R8C.tplbond.CCR6R7ZYXNR5CHR11CHR12CONHOH, R8C.tplbond.CCR6R7ZYXNR5CHR11:CR12CONHOH [X = SO₂, P(O)R₁₀; Y = heteroaryl, Ph, naphthyl; Z = O, NH, CH₂, S; R₅ = H, alkyl; R₆, R₇ = H, Me; R₈ = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, Ph, etc.; R₁₀ = alkyl, cycloalkyl, Ph, heteroaryl; R₁₁, R₁₂ = H, alkyl, cycloalkyl, heteroaryl, Ph; R₁₁R₁₂ = atoms to form (fused) (unsatd.) ring; with provisos], were prepared Thus, (1R,2S)-2-[[4-(2-butynyloxy)phenyl]sulfonyl](methylamino)-N-hydroxycyclopentanecarboxamide (general preparation given) inhibited TNF-α converting enzyme (TACE) with IC₅₀ = 14 nM.
OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD.
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

10593748

L9 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2000:553546 HCAPLUS
 DOCUMENT NUMBER: 133:150358
 TITLE: Preparation of sulfonamide derivatives having cyclic structures as matrix metalloprotease inhibitors and TNF production inhibitors
 INVENTOR(S): Watanabe, Fumihiko; Tsuzuki, Hiroshige
 PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046189	A1	20000810	WO 2000-JP446	20000128
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 1999-25058	A 19990202

OTHER SOURCE(S): MARPAT 133:150358
 GI




AB The title derivs. I [A is Q1, etc.; R1 is COOR6 or the like; R6 is hydrogen, alkyl; R2 is optionally substituted arylene or the like; R3 is CONH or the like; R4 is optionally substituted aryl or the like; R5 is hydrogen or the like; and m and n are each independently 0 or 1] are prepared. The title compound II in vitro showed IC50 of 9.7 μ M against MMP-8. Formulations are given.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD

L9 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2000:535104 HCAPLUS
 DOCUMENT NUMBER: 133:150361
 TITLE: Preparation of alkynylloxypheylsulfonaminoalkylhydroxamic acids and related compounds as TNF- α converting enzyme (TACE) inhibitors.
 INVENTOR(S): Levin, Jeremy Ian; Chen, James Ming; Zask, Arie
 PATENT ASSIGNEE(S): American Cyanamid Company, USA
 SOURCE: PCT Int. Appl., 58 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044711	A1	20000803	WO 2000-US1865	20000127
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356345	A1	20000803	CA 2000-2356345	20000127
EP 1147078	A1	20011024	EP 2000-904570	20000127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007754	A	20011113	BR 2000-7754	20000127
HU 2002000605	A2	20020729	HU 2002-605	20000127
HU 2002000605	A3	20050530		
JP 2002535383	T	20021022	JP 2000-595968	20000127
NZ 512025	A	20030829	NZ 2000-512025	20000127
AU 769410	B2	20040129	AU 2000-26306	20000127
ZA 2001004508	A	20020902	ZA 2001-4508	20010531
NO 2001003639	A	20010724	NO 2001-3639	20010724
MX 2001007465	A	20011203	MX 2001-7465	20010724
PRIORITY APPLN. INFO.:			US 1999-239083	A 19990127
			WO 2000-US1865	W 20000127

OTHER SOURCE(S): MARPAT 133:150361
 GI



L9 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 (6 CITINGS)
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L9 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
 AB Title compds. (I; X = SO2, POR10; Y = 5-10 membered heteroaryl, Ph, naphthyl; Z = O, NH, CH2, S; R5 = H, alkyl; R6, R7 = H, Me; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycloalkyl, Ph; R9 = H, alkyl, cycloalkyl, Ph; R10 = alkyl, cycloalkyl, Ph, heteroaryl; R11, R12 = H, alkyl, cycloalkyl, heteroaryl, heterocycloalkyl; R11R12 = atoms to form 5-10 membered mono- or bicyclic (heterocyclic) ring, Ph, naphthyl; dotted line = optional double bond), were prepared. Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxycyclopentanecarboxamide [preparation from cis-2-amino-1-cyclopentanecarboxylic acid and 4-(2-butynyloxy)phenylsulfonyl chloride given] inhibited TACE with IC50 = 14 nM.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

REFERENCE COUNT: 8 (4 CITINGS)
 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

10593748

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

52.24

519.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-8.70

-15.66

STN INTERNATIONAL LOGOFF AT 09:58:14 ON 22 FEB 2011